Africa
Novartis reports positive opinion from CHMP for Xolair® in severe form of skin disease CSU, a debilitating form of hives and chronic itch
Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the use of Xolair® (omalizumab) as an add-on therapy for […]